Foley Hoag Represents deCODE Genetics in $415 Million Sale to Amgen
January 29, 2013
Foley Hoag LLP congratulates deCODE Genetics in its recently announced $415 million acquisition by Amgen Inc.
Headquartered in Reykjavik, Iceland, deCODE Genetics is a global leader in analyzing and understanding the link between the genome and disease susceptibility. Using its unique expertise and access to a well-defined population, deCODE Genetics has discovered genetic risk factors for dozens of diseases ranging from cardiovascular disease to cancer.
Foley Hoag partners Robert Birnbaum and Robert Warren represented deCODE Genetics in the transaction, with support from others at the firm, including partners Arlene Bender, Teresa Martland and Earl Mellott, and associates Adrienne Ellman and Erica Rice.
“We are honored to represent deCODE genetics, and congratulate them on this milestone agreement,” Birnbaum said. “This deal allows deCODE to continue their cutting-edge human genetics research, and we wish them much success in the future.”
About Foley Hoag LLP
Foley Hoag provides innovative, strategic legal services to public, private and government clients across the globe. We have premier capabilities in the life sciences, healthcare, technology, energy, professional services and investment management fields, and in cross-border disputes. Our professionals possess the skills and experience to provide exceptional senior level service to clients ranging from startups to multinational companies to sovereign states. For more information, visit www.foleyhoag.com or follow @FoleyHoag on Twitter.